GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (LSE:APTA) » Definitions » Capex-to-Revenue

Aptamer Group (LSE:APTA) Capex-to-Revenue : 0.13 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Aptamer Group Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Aptamer Group's Capital Expenditure for the six months ended in Dec. 2023 was £-0.04 Mil. Its Revenue for the six months ended in Dec. 2023 was £0.30 Mil.

Hence, Aptamer Group's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.13.


Aptamer Group Capex-to-Revenue Historical Data

The historical data trend for Aptamer Group's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group Capex-to-Revenue Chart

Aptamer Group Annual Data
Trend Mar19 Mar20 Jun22 Jun23
Capex-to-Revenue
0.04 0.19 0.10 1.16

Aptamer Group Semi-Annual Data
Mar19 Mar20 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial 0.44 -0.07 1.74 0.36 0.13

Competitive Comparison of Aptamer Group's Capex-to-Revenue

For the Biotechnology subindustry, Aptamer Group's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptamer Group's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptamer Group's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aptamer Group's Capex-to-Revenue falls into.



Aptamer Group Capex-to-Revenue Calculation

Aptamer Group's Capex-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.028) / 1.752
=1.16

Aptamer Group's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.04) / 0.298
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptamer Group  (LSE:APTA) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Aptamer Group Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aptamer Group's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptamer Group Business Description

Traded in Other Exchanges
Address
Innovation Way, Windmill House, York, GBR, YO10 5BR
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.

Aptamer Group Headlines

No Headlines